The Food and Drug Administration (FDA) has approved the combination of nivolumab (Opdivo ®) plus ipilimumab (Yervoy ® ), both from Bristol Myers Squibb Company, as an option for first-line therapy for ...

Researchers evaluated opioid prescribing trends by provider type for emergency department visits at noninstitutional and short-stay hospitals from 2019 to 2021.

Investigators studied cancer incidence, survival outcomes, and graft function among a multicenter cohort of kidney transplant recipients.

Patients with MSI-H mCRC had a higher probability of survival with first-line ICI therapy than with chemotherapy, but second-line or later ICIs did not confer the same benefit.

HealthDay News — Exercise and rehabilitation services for patients with breast cancer through a clinical workflow algorithm called CORE (Comprehensive Oncology Rehabilitation and Exercise) is feasible ...